Preservative-free fixed-dose combination of tafluprost 0.0015% / timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: Clinical effectiveness, tolerability and safety in a real world setting (Taptiqom)

First published 11/01/2018

Last updated 02/07/2024

EU PAS number:

EUPAS22204

Study

Finalised

Documents

Study protocol

Initial protocol

Taptiqom_Santen_PhIV_Protocol v2.0

English (2.04 MB - PDF)View document

Updated protocol

Amended Protocol V5 13Feb2018_ clean_ Eng_Final (review 14feb18)_signed

First published: 22/02/2024

English (1.05 MB - PDF)View document

Study results

Study report

Other information

Study, other information

Glaucoma_All_site

English (43.95 KB - PDF)View document

sites final 0240-0024

English (47.27 KB - PDF)View document

Secondary tabs